Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01713
|
|||||
| Drug Name |
S-licarbazepine
|
|||||
| Synonyms |
Eslicarbazepine; (S)-10-Hydroxy-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; S-licarbazepine; UNII-S5VXA428R4; BIA 2-194; S-10-Monohydroxy-dihydro-carbamazepin; S5VXA428R4; S-(+)-10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide; (5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide; (10S)-10,11-Dihydro-10-hydroxy-5H-Dibenz[b,f]azepine-5-carboxamide; (S)-Licarbazepine; S(+)-Liscarbazepine; (10S)-10,11-Dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxamide
|
|||||
| Indication | Partial seizures [ICD11: 8A68.0] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C15H14N2O2
|
|||||
| Canonical SMILES |
C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O
|
|||||
| InChI |
InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)/t14-/m0/s1
|
|||||
| InChIKey |
BMPDWHIDQYTSHX-AWEZNQCLSA-N
|
|||||
| CAS Number |
CAS 104746-04-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 254.28 | Topological Polar Surface Area | 66.6 | ||
| Heavy Atom Count | 19 | Rotatable Bond Count | 0 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 2 | |||
| XLogP |
1.4
|
|||||
| PubChem CID | ||||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Eslicarbazepine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia. 2011 Oct;52(10):1894-904. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.